« Seattle Times on Medtronic - not a case... | Main | UN resolution on diabetes passed! »


Eli Lilly's motion to suppress the evidence has been denied by an inter-galactic court of appeals. Justice will be served over HTTP.

As we speak, the slick marketing plans drawn up by the smartest boys in the drug dealing business are propagating across the Internet. Bittorrents have been internationally seeded; p2p networks like morpheus, kaaza, gnutella, and limewire are already trading vigorously; photos laced with the data have been posted to public photo sharing sites like flickr; movies containing slideshows are circulating on video sharing sites like YouTube; Usenet isn't obsolete yet, and yes, backups have been uploaded to freenet (freenetproject.org), the virtual data haven;

Information wants to be free. Look for a file named ZyprexaKills, or any of its l33t variants.

For those of you without easy access to these services we have temporarily posted these files in this convenient location:


Please be careful when obtaining them - we are up against some of the most greedy and powerful elites in the world.You may want to consider using the tor program (tor.eff.org) to preserve your anonymity. If its difficult for you to install this program, try www.torify.com, a web based surfing solution.

Send this message to as many friends and mailing lists that you can think of, especially the technically saavy and the media connected.

Please tag all netroots activity and distributed research relating to this campaign with the tag 'zyprexakills'.

This message is also available at:


Agent Fred

Eli Lilly Zyprexa scandal

Zyprexa off label promotion scandal is all over the news now.
Lilly drug reps are alleged to have called their marketing ploy,"Viva zyprexa".

Eli Lilly zyprexa cost me over $250.00 a month supply out of my own pocket X 4 years and has up to ten times the risk (over non users) of causing diabetes and severe weight gain.

Zyprexa which is only FDA approved for schizophrenia (.5-1% of pop) and some bipolar (2% pop) and then an even smaller percentage of theses two groups.
So how does Zyprexa get to be the 7th largest drug sale in the world?
Eli Lilly is in deep trouble for using their drug reps to 'encourage' doctors to write zyprexa for non-FDA approved 'off label' uses.

The drug causes increased diabetes risk,and medicare picks up all the expensive fallout.There are now 7 states (and counting) going after Lilly for fraud and restitution.

Only 9 percent of adult Americans think the pharmaceutical industry can be trusted right around the same rating as big tobacco.

Daniel Haszard zyprexa-victims.com

For what its worth, today "A Statement from Eli Lilly and Company: Response to The New York Times Article from December 18, 2006". In their response, they note:

"The Times failed to mention that these leaked documents are a tiny fraction of the more than 11 million pages of documents provided by Lilly as part of the litigation process. They do not accurately portray Lilly's conduct. As part of Lilly's commitment to patients and healthcare professionals, many high-level Lilly physicians and researchers -- along with researchers from outside Lilly -- were engaged for a number of years to study the issue of Zyprexa and diabetes. Leaked documents involving these discussions do not represent an accurate view of company strategy or conduct.

Lilly deplores the illegal release of select confidential documents. This illegal and selective disclosure of incomplete information will cause unwarranted concern among patients that may cause them to stop taking their medication without consulting a physician. This is the unfortunate result we saw when plaintiffs' lawyers aggressively advertised about Zyprexa in recent years while searching for clients."

A few observations:

a) the Times article raises questions about how Lilly marketed this product and

b) there are already concerns about Lilly's Zyprexa, insulin franchise, and Evista businesses, and considering Lilly's earnings rely heavily on Zyprexa, which generated
30% of total 2005 sales and, by some estimates, about one-third of Lilly's total income, this could be a problem.

c) Lilly has a uninspiring late-stage drug pipeline for the diabetes business (basically, a line extension to the Byetta product), but nothing imminent on the basal insulin analog front and

d) the company is boosting its salesforce for the diabetes business by another 40% to market the Humapen Memoir product, as well as pen devices for Byetta and Symlin, although many suspect this may be due to Novo's recent announcement to add another 800 sales reps to about 1,900 in the U.S.

Collectively, these things suggest that Lilly may be overvalued (many analysts rate it a hold right now) and they will need to make significant investments in the diabetes business to maintain share and earnings, which will put further pressure on that business. The Zyprexa article was a troubling development for the company.

The comments to this entry are closed.